Immunotherapy News and Research

Latest Immunotherapy News and Research

Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has entered into a structured collaboration with the laboratory of Dr. Tobias Kollmann at the University of British Columbia (UBC) to develop live attenuated Listeria vaccines for the treatment of infectious disease and for new dosage forms of Listeria vaccines.

9 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

Antigenics awarded $424,720 grant under QTDP program

Antigenics Inc. today announced that it has been awarded $424,720 in grants under the IRS' Qualifying Therapeutic Discovery Project (QTDP) program. The grants were awarded in recognition of our two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon® adjuvant.

4 Nov 2010

Aduro receives $442,000 grant under QTDP program to support Listeria-based immunotherapy platform

Aduro BioTech announced today that it has been awarded two cash grants totaling approximately $442,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

Celldex third quarter net loss increases to $9.1 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.

2 Nov 2010

Advaxis enters CRADA with NCI for development of live attenuated Listeria vaccines

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, is pleased to announce it has signed a formal research agreement with the National Cancer Institute at the National Institutes of Health.

30 Oct 2010

MannKind third quarter operating expenses decreases from $42.8 million to $42.5 million

MannKind Corporation today reported financial results for the third quarter ended September 30, 2010.

29 Oct 2010

New findings on Th17 cells pave way for human cancer treatment protocol

A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

29 Oct 2010

International Congress at Spain highlights advances in neuroimmunological disease treatment

The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine. Between October 26th and 30th takes place in Sitges (Barcelona, Spain) the X International Congress of Neuroimmunology of the International Society of Neuroimmunology.

29 Oct 2010

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

IDC grants MedImmune global rights to GLA adjuvant

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

26 Oct 2010

New epilepsy drugs give more options, but make treatment decisions more complex: Epilepsy specialist

A dozen new epilepsy drugs are giving doctors and patients more options, but making treatment decisions more complex, a Loyola epilepsy specialist reports in the journal Neurologic Clinics.

22 Oct 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.

22 Oct 2010

LSUHSC receives NIH grant for research on cancer and infectious diseases

LSU Health Sciences Center New Orleans has been awarded $12 million over five years by the National Institutes of Health to conduct research on diseases like prostate and stomach cancers, lymphoma and leukemia, dengue fever, tuberculosis, and herpes infections, as well as to support the development of academic research scientists.

21 Oct 2010

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ profiling service and immunoSEQ Analyzer bioinformatics software platform. Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

21 Oct 2010

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

NYU Langone Medical Center is pleased to announce that it has established The Smilow Comprehensive Prostate Cancer Center with a $5 million gift from Joel E. Smilow, a member of the Board of Trustees at NYU Langone Medical Center and New York University. The Smilow Center is dedicated to providing comprehensive, state-of-the-art personalized care for men with prostate cancer as well as educating men and their families about the disease and the wide range of treatment options available today.

21 Oct 2010

Immunotherapy News and Research

Latest Immunotherapy News and Research

Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

NWBT receives $490,000 in two grants under QTDP program

Antigenics awarded $424,720 grant under QTDP program

Aduro receives $442,000 grant under QTDP program to support Listeria-based immunotherapy platform

Top 10 Medical Innovations for 2011

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Celldex third quarter net loss increases to $9.1 million

Advaxis enters CRADA with NCI for development of live attenuated Listeria vaccines

MannKind third quarter operating expenses decreases from $42.8 million to $42.5 million

New findings on Th17 cells pave way for human cancer treatment protocol

International Congress at Spain highlights advances in neuroimmunological disease treatment

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

IDC grants MedImmune global rights to GLA adjuvant

New epilepsy drugs give more options, but make treatment decisions more complex: Epilepsy specialist

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

LSUHSC receives NIH grant for research on cancer and infectious diseases

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in